Date: 6/6/2007 9:00:00 AM
West Bridgewater, MA, June 6, 2007 – Pressure BioSciences, Inc. (NASDAQ: PBIO) ("PBI") today announced that it has developed a novel, potentially revolutionary method for the safe, rapid, efficient, and reproducible extraction of proteins from lipid-rich samples, including adipose and brain tissues, organelles, and membrane preparations. This patent-pending method combines the use of the Company’s pressure cycling technology (PCT) with certain organic solvents. This method offers a significant advantage over existing techniques in that it enables protein extraction from lipid-rich samples without the use of detergents. This is important because detergents can cause serious problems in the subsequent analysis of these samples. The Company plans to discuss its findings this morning at a scientific poster session of the American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry being held in Indianapolis, Indiana.
Proteomic analysis of lipid-rich tissue is used in studies of type II diabetes, obesity, certain cancers, ALS, and a number of other serious human disorders. Current detergent-based methods for the extraction of proteins from lipid-rich samples can generate highly variable results, increasing the cost and processing time for the extraction and compromising the quality and quantity of the recovered proteins. Any method that can avoid the use of detergents may offer valuable advantages to researchers studying tissues rich in lipids. Data to be presented at ASMS Conference on Mass Spectrometry by the Company and its collaborators at the Harvard School of Public Health suggest that costs can be reduced, experimental protocols streamlined, and that the quality and quantity of protein recovery may be improved when lipid-rich tissues are processed with the Company’s newly developed PCT-dependent, detergent-free process. The Company believes that these advantages should benefit the thousands of researchers throughout the world who routinely study lipid-rich samples.
Dr. Alexander Lazarev, Vice President of Research and Development of PBI, said: “Our data indicate that we can achieve nearly complete dissolution of lipid-rich tissue samples with our PCT-dependent, detergent-free protein extraction method. Our data also suggest that proteins and lipids can be isolated as two distinct fractions in a single step, thus allowing for the independent analysis of these molecules from a single sample in a far more rapid and efficient manner than possible with current methods. Finally, based on our results, we believe that lipids and proteins obtained using the PCT-dependent method will not require any additional purification to be directly compatible with HPLC, LC/MS analysis, and gel electrophoresis. This should avoid additional cost and time for the researcher, advantages that could subsequently help advance drug discovery in such important biomedical research areas as diabetes, obesity, certain cancers, and neurological disorders. These are very exciting results.”
Dr. Alexander R. Ivanov, a researcher at the Harvard School of Public Health, and a co-author on the poster presentation, commented: “We are very pleased with the results generated to date. We observed higher yields of proteins with the PCT-dependent, detergent-free method than we would have expected with our standard extraction procedures. We also found that the PCT method was straight-forward and easy-to-use, and gave us excellent quality of results. Perhaps most importantly, however, we extracted several proteins with the PCT method that were not previously released by standard, detergent-based extraction techniques. We are optimistic that this new PCT-dependent, detergent-free method will help to accelerate our research efforts.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 U.S. and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law
Visit us at our website http://www.pressurebiosciences.com
CONTACT:
Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 580-1818
© 2003-2007 Accelerize New Media, Inc. All rights reserved.
SECFilings.com is not affiliated with or approved by the SEC and shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Replication or redistribution of SECFilings.com content is expressly prohibited without the prior written consent of Accelerize New Media, Inc.